Steven Perrin - Jan 10, 2025 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELDN	Stock Option (right to buy)	Award	$0	+243K		$0.00	243K	Jan 10, 2025	Common Stock	243K	$4.04	Direct	F1
transaction	ELDN	Restricted Stock Units	Award	$0	+27K		$0.00	27K	Jan 10, 2025	Common Stock	27K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This option represents a right to purchase up to 243,000 shares of common stock, which option vests with respect to 60,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2	Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
F3	Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.